New supplement shows promise for soothing heartburn
NCT ID NCT06889246
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a liquid dietary supplement called Anvitra Gastric Suspension can reduce heartburn, regurgitation, and indigestion in people with GERD. Twenty-seven adults took the supplement three times daily for 14 days. Researchers measured symptom changes using a standard questionnaire and tracked any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Anvitra Gastric Suspension (a dietary supplement)
- What this could lead to
- If it works, this could point toward a safe, over-the-counter option to ease heartburn and reflux symptoms.
- What could go wrong
- This is a very small, early trial with only 27 people and no placebo group. The supplement may not work better than existing treatments or a dummy pill.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
27 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 years or older at the time of signing the ICF 2. Diagnosis of GERD 3. Los Angeles Grade A or B esophagitis 4. Symptoms of heartburn, reflux, or dyspepsia 5. The participant is willing and able, in the opinion of the investigator, to modify current GERD therapy as required by the protocol. 6. Ability to sign an informed consent form for participation in the study as described in Appendix A, including compliance with the requirements and restrictions listed in the ICF and in this protocol. Exclusion Criteria: 1. Concomitant esophageal stenosis, tumors, esophageal cancer, Barrett's esophagus, stomach cancer, gastric ulcer: confirmed by the results of esophagogastroduodenoscopy at the first examination and/or medical records 2. History of other gastrointestinal diseases, severe diseases of other organs 3. Esophagitis grade C, D according to the Los Angeles classification 4. Unable to perform esophagogastroduodenoscopy: esophageal diseases that can cause esophageal perforation (esophageal burns due to chemicals, drugs causing esophageal stenosis), thoracic aortic aneurysm, heart failure, myocardial infarction, hypertensive crisis, respiratory failure, difficulty breathing due to any cause, severe cough, severe scoliosis, elderly patients, mentally ill patients who cannot cooperate, hypotension, patients who do not agree to perform. 5. Severe hepatic or renal impairment and other chronic medical conditions. 6\. Current use of medications that affect the gastrointestinal tract, medications that are known to cause or aggravate gastroesophageal reflux disease. 7\. Participation in another clinical study with a study intervention performed within the last 14 days. 8\. Planned hospitalization during the study. 9\. The investigator's judgment that the participant should not participate in the study if the participant is unable to comply with the study procedures, restrictions and requirements. 10\. Women only: currently pregnant (confirmed by a positive pregnancy test), breastfeeding or planning to become pregnant during the study, or not using acceptable contraception.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERD (heartburn, regurgitation, and dyspepsia) frequency are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Clinical Trial and Bioequivalence Study
Haiphong, Hải Phòng, Vietnam
-
Center for Clinical Trial and Bioequivalence Study, Haiphong University of Medicine and Pharmacy
Haiphong, Vietnam